Progenika Biopharma S.a.

Grifols Diagnostic Solutions Inc.

Proteomika, S.l.

Daniel Nagore Casas

Antonio Martinez Martinez

Laureano Simón Buela

Antonio Martínez Martínez

Alberto Monasterio Asteinza

Nerea Torres Antúnez

Elizabeth Booth

Jody Berry

Ainhoa Ruiz Del Agua

Joyee Antony George

Elisabete Nascimento

A lateral flow immunoassay for the detection of anti-drug antibodies against a biological drug includes a membrane having a capture area, a sample application area, a flow path from the sample application area to the capture area, and a conjugate area located in the flow path. The conjugate area has said biological drug detectably labeled and the capture area has said biological drug immobilized thereto.

Lateral flow immunoassays for the detection of antibodies against biological drugs

Fusion proteins comprising an extracellular domain of PD1 (programmed cell death protein-1) protein and/or an extracellular domain of PD-L1 (programmed cell death-ligand 1 protein (CD274 or B7-H1)) protein. Portions of the extracellular domains are expressed in specific configurations and purified as protein and used in immunoassays to monitor the circulating levels of biotherapeutic antibodies to these proteins. Also described is a method of determining the amount of circulating levels of a biotherapeutic antibody in a biological sample obtained from a patient, wherein a patient has undergone at least one dose of immunotherapy.

Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors PD1 and PD-L1

The invention relates to the field of personalized therapy and, in particular, to a method for classifying a patient suffering from rheumatoid arthritis as a responder or as a non-responder patient to a treatment based on a biological drug.

Method to optimize the treatment of patients with biological drugs

Growing community of inventors

Derio, Spain

Daniel Nagore Casas